In preclinical trials, H3B-6527 proved to be effective in terms of repressing tumor growth in a xenograft model of HCC which exhibited activated aberrant FGF19–FGFR4 signaling [65]. This evidence concerns the gene FGFR4 and hepatocellular carcinoma.